 Novartis AG NYSE: NVS has announced topline results from an interim analysis of the Phase 3 RATIONALE 306 study of tislelizumab plus chemotherapy in esophageal squamous cell carcinoma ESCC. Data showed that tislelizumab plus chemotherapy significantly improved overall survival . 